araag2/HINT huggingface dataset:
Clinical trial NCT01285492 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease (copd)
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: qva149, tiotropium
SMILES: C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with moderate to severe stable COPD (Stage II or Stage III) according to the
             Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines 2008.

          -  Current or ex-smokers who have a smoking history of at least 10 pack years. (Ten pack
             years are defined as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20
             years etc.)

          -  Patients with post-bronchodilator forced expiratory volume in one second (FEV1) ≥30%
             and < 80% of the predicted normal, and post-bronchodilator FEV1/forced vital capacity
             (FVC) < 0.7 at Visit 2.

        Exclusion Criteria:

          -  Pregnant women or nursing mothers or women of child-bearing potential not using an
             acceptable method of contraception

          -  Patients requiring long term oxygen therapy

          -  Patients who have had a lower respiratory tract infection within 4 weeks prior to
             Visit 1

          -  Patients with concomitant pulmonary disease

          -  Patients with a history of asthma

          -  Any patient with history of malignancy of any organ system (including lung cancer),
             treated or untreated, within the past 5 years

          -  Patients with a history of certain cardiovascular comorbid conditions

          -  Patients with a known history and diagnosis of alpha-1 antitrypsin deficiency

          -  Patients in the active phase of a supervised pulmonary rehabilitation program

          -  Patients contraindicated for treatment with, or having a history of reactions/
             hypersensitivity to anticholinergic agents, long and short acting beta-2 agonists,
             sympathomimetic amines

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00362232 (phase 3, status: completed)
Conditions: venous thromboembolism
ICD codes: O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: rivaroxaban (xarelto, bay59-7939), enoxaparin, placebo: tablet of rivaroxaban, placebo: syringes of enoxaparin
SMILES: ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female patients aged 18 years or above

          -  Patients scheduled for elective total knee replacement

        Exclusion Criteria:

          -  Active bleeding or high risk of bleeding contraindicating treatment with Low Molecular
             Weight Heparin (LMWH)

          -  Contraindication listed in the labeling or conditions precluding subject treatment
             with enoxaparin or requiring dose adjustment (e.g. severe renal impairment, please
             refer to the local label of enoxaparin in your country)

          -  Conditions prohibiting bilateral venography (e.g. amputation of 1 leg, allergy to
             contrast media)
Clinical trial NCT00300495 (phase 3, status: terminated)
Conditions: atrial fibrillation, lung cancer
ICD codes: I48.0, I48.21, I48.91, I48.11, I48.19, I48.20, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: amiodarone
SMILES: CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
Reason stopped: 
    unable to accrual total number of participants during study period.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Resectable lung nodule or mass

        Exclusion Criteria:

          -  Allergy to amiodarone

          -  Currently taking amiodarone

          -  Documented atrial fibrillation within past 12 months

          -  Known pulmonary fibrosis

          -  Known hepatic dysfunction

          -  Thyroid disease

          -  2nd or 3rd degree heart block

          -  Severe SA node disease

          -  Bradycardia-induced syncope

          -  Pregnancy
Clinical trial NCT00411268 (phase 3, status: completed)
Conditions: low back pain
ICD codes: M54.50, M54.51, M54.59
Drugs: oros hydromorphone hci sr (slow release)
SMILES: [H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who have chronic low back pain who have successfully completed short-term
             Study DO-127 with OROS hydromorphone slow release

          -  Patients who require at least 8 mg of hydromorphone HCI (slow release) every 24 hours
             for the management of chronic low back pain

          -  Patients whose opioid requirements have been stable as demonstrated in short-term
             Study DO-127 with OROS hydromorphone slow release

        Exclusion Criteria:

          -  Patients intolerant of or hypersensitive to hydromorphone (or other opioid agonists)

          -  Patients who are pregnant or breast-feeding

          -  Patients with any gastrointestinal disorder, including pre-existing severe GI
             narrowing (pathologic or iatrogenic) that may affect the absorption or transit of
             orally administered drugs

          -  Patients with significant CNS disorder, including but not limited to head injury,
             intracranial lesion, increased intracranial pressure, seizure disorder, stroke within
             the past 6 months, disorders of cognition, any clinically significant impaired renal
             or hepatic function, Addison's disease, hypothyroidism, prostatic hypertrophy, or
             urethral stricture

          -  Patients who may be at risk for serious decreases in blood pressure upon taking an
             opioid analgesic
Clinical trial NCT01076088 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: sitagliptin 50 mg, metformin 500 mg, sitagliptin 100 mg, placebo, metformin 850 mg
SMILES: N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CN(C)C(=N)NC(N)=N, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  has type 2 diabetes mellitus

          -  is male, a female who cannot have children, or a female who agrees to use birth
             control during the study

          -  is not on an antihyperglycemic agent (AHA) (hemoglobin A1c [A1C] 7.5-11.0%) or on oral
             single AHA (A1C 7.0-10.5%) or low-dose AHA combination therapy (A1C 7.0-10.0%)

        Exclusion Criteria:

          -  Patient has type 1 diabetes mellitus or ketoacidosis

          -  Patient is taking a dipeptidyl peptidase-4 (DPP-4) inhibitor (such as sitagliptin)

          -  Patient is on a weight loss program not in the maintenance phase or on a weight loss
             medication

          -  Patient has a history of liver disease, heart failure, heart disease, stroke, high
             blood pressure, blood disorders, or cancer

          -  Patient is HIV positive

          -  Patient is pregnant
Clinical trial NCT00720408 (phase 3, status: completed)
Conditions: liver transplantation, transplantation immunology, host vs graft reaction
ICD codes: Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, K70.0
Drugs: prograf-xl, prograf, mmf
SMILES: CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, COC(=O)\C=C\C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient has been fully informed and has signed an IRB approved informed consent form
             and is willing and able to follow study procedures

          -  Patient is a primary liver transplant recipient

          -  Patient must receive first dose of XL or Prograf (or IV tacrolimus for subjects unable
             to tolerate oral study drug) within 48 hours of transplantation

          -  Female patients of child bearing potential must have a negative urine or serum
             pregnancy test within 7 days prior to transplant

        Exclusion Criteria:

          -  Patient has previously received or is receiving an organ transplant other than a liver

          -  Recipient or donor is known to be seropositive for human immunodeficiency virus (HIV)

          -  Patient has received a liver transplant from a non-heart beating donor

          -  Patient has received an ABO incompatible donor liver

          -  Patient has a current malignancy or a history of malignancy (within the past 5 years),
             except hepatocellular carcinoma within UCSF Criteria 21 and basal or non-metastatic
             squamous cell carcinoma of skin that has been treated successfully

          -  Patient has fulminant hepatic failure, unless hemodynamically stable

          -  Patient has an uncontrolled concomitant infection, a systemic infection requiring
             treatment (except viral hepatitis), or any other unstable medical condition that could
             interfere with the study objectives

          -  Patient has severe diarrhea, vomiting, active peptic ulcer or gastrointestinal
             disorder that may affect the absorption of tacrolimus

          -  Patient is currently taking or has been taking an investigational drug in the 30 days
             prior to transplant

          -  Patient has a known hypersensitivity to tacrolimus, mycophenolate mofetil or
             corticosteroids

          -  Patient is pregnant or lactating

          -  Patient is unlikely to comply with the visits scheduled in the protocol, including the
             protocol biopsies

          -  Patient has any form of substance abuse, psychiatric disorder or a condition that, in
             the opinion of the investigator, may invalidate communication with the investigator
Clinical trial NCT01127750 (phase 3, status: completed)
Conditions: relapsing multiple sclerosis
ICD codes: M94.1, A68.9, A68.0, A68.1, M35.6
Drugs: fty720
SMILES: CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  18-65 years of age, must have relapsing MS

        Exclusion Criteria:

          -  Patients with a type of MS that is not relapsing

          -  Patients with history of chronic immune disease

          -  Patients with a history of certain cancers

          -  Diabetic patients with certain eye disorders

          -  Patients who are on certain immunosuppressive medications or heart medications

          -  Patients with certain heart conditions

          -  Patients with certain lung conditions

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00336947 (phase 3, status: unknown status)
Conditions: head and neck cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: tegafur-gimeracil-oteracil potassium, tegafur-uracil
SMILES: FC1=CN(C2CCCO2)C(=O)NC1=O, O=C1NC=CC(=O)N1.FC1=CN(C2CCCO2)C(=O)NC1=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed squamous cell carcinoma of the head and neck
             (SCCHN)

               -  Stage III or IV disease

               -  Primary tumor in the mesopharynx, hypopharynx, larynx (except T3 N0 tumors of the
                  glottis), oral cavity, or maxillary sinus

          -  Completed definitive treatment for SCCHN within the past 3 months, that included any
             of the following:

               -  Surgery

               -  Chemotherapy

               -  Biologic therapy

               -  Radiotherapy (e.g., radiotherapy in combination with chemotherapy or pre- or
                  postoperative radiotherapy)

               -  Any other treatment

          -  No clinical evidence of locoregional tumors or distant metastasis within 3 months
             after the completion of definitive treatment

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-1

          -  WBC ≥ 3,500/mm^3 AND ≤ 12,000/mm^3

          -  Neutrophil count ≥ 2,000/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 9 g/dL

          -  AST and ALT < 100 IU/L

          -  Bilirubin < 1.5 mg/dL

          -  Creatinine < 1.2 mg/dL

          -  No uncontrolled cardiovascular disease

          -  No interstitial pneumonia or pulmonary fibrosis

          -  Must have sufficient oral intake

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No concurrent biologic therapy, radiotherapy, other chemotherapy, or any other therapy
Clinical trial NCT00174265 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: asenapine, olanzapine
SMILES: OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1, CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Continue to meet all demographic and procedural

        inclusion criteria of the A7501013 trial to enter into

        this extension trial.

          -  Have demonstrated an acceptable degree of compliance

        and completed the A7501013 trial, and would benefit

        from continued treatment according to the investigator.

        Exclusion Criteria:

          -  Have an uncontrolled, unstable clinically significant

        medical condition.

          -  Have been judged to be medically noncompliant in the

        management of their disease.
Clinical trial NCT00344968 (phase 3, status: completed)
Conditions: diabetic macular edema
ICD codes: E10.311, E10.319, E11.311, E11.319, E13.311, E13.319, E10.3513
Drugs: fluocinolone acetonide, fluocinolone acetonide
SMILES: [H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO, [H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO
Eligibility criteria:

        Inclusion Criteria:

          -  Age >= 18 years with diabetic macular edema

          -  Diagnosis of diabetes mellitus types 1 or 2

          -  Best corrected visual acuity of 19-68 letters

          -  Retinal thickness > 250 micron by OCT

          -  Investigator is comfortable deferring macular laser treatment for 6 weeks

        Exclusion Criteria:

          -  Glaucoma, ocular hypertension, IOP >21 mmHg or concurrent therapy at screening with
             IOP lowering agents

          -  Retinal or choroidal neovascularization due to ocular conditions other than diabetic
             retinopathy

          -  Prior intravitreal, subtenon, or periocular steroid therapy within 6 months

          -  Any ocular surgery within the last 3 months

          -  Retinal laser treatment within the last 3 months

          -  History of uncontrolled IOP elevation with steroid use that did not respond to topical
             therapy

          -  Any lens opacity which impairs visualization of the posterior pole
Clinical trial NCT00003034 (phase 3, status: unknown status)
Conditions: malignant mesothelioma
ICD codes: C45.9, C45.0, C45.1, C45.2, C45.7
Drugs: doxorubicin hydrochloride, ranpirnase
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed malignant pleural or peritoneal mesothelioma

               -  Measurable or evaluable disease

          -  CALGB groups 1-4

          -  No CNS metastases

        PATIENT CHARACTERISTICS:

        Age:

          -  21 and over

        Performance status:

          -  ECOG 0-1

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  WBC greater than 3,500/mm^3

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  SGOT no greater than 2 times upper limit of normal

          -  Bilirubin no greater than 2 mg/dL

          -  PT and PTT normal

        Renal:

          -  Creatinine normal

        Cardiovascular:

          -  No symptomatic New York Heart Association class II-IV cardiovascular disease

          -  No congestive heart failure

          -  No angina pectoris

          -  No cardiac arrhythmias

          -  No uncontrolled hypertension

          -  No cerebrovascular disease

        Metabolic:

          -  No serum calcium, phosphate, electrolyte, or other metabolic abnormalities, such as
             metabolic acidosis

        Other:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No serious infection

          -  No uncontrolled psychosis or neurologic disease (e.g., seizure disorders)

          -  No uncontrolled diabetes mellitus

          -  No other primary malignancy within the past 5 years except nonmelanoma skin cancer

          -  No senility or emotional instability

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No more than one prior systemic chemotherapy regimen

          -  No prior doxorubicin

          -  At least 6 weeks since prior chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  Prior radiotherapy for progressive or recurrent disease allowed except myocardium
             radiotherapy

        Surgery:

          -  Prior surgical resection allowed
Clinical trial NCT01180634 (phase 3, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: mp-376 (levofloxacin solution for inhalation), placebo
SMILES: C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria (selected):

          -  >/= 12 years of age

          -  Confirmed Diagnosis of Cystic Fibrosis

          -  Positive sputum culture for P. aeruginosa at screening and within the past 12 months

          -  Patients are able to elicit an FEV1 >/= 25% but </= 85% of predicted value at
             screening

          -  Have received at least 3 courses of inhaled antimicrobials over the preceding 12
             months

          -  Clinically stable with no changes in health status within the last 28 days

          -  Able to reproducibly produce sputum and perform spirometry

        Exclusion Criteria (selected):

          -  Use of any nebulized or systemic antibiotics within 28 days prior to baseline

          -  History of hypersensitivity to fluoroquinolones or intolerance with aerosol medication

          -  Evidence of respiratory infections within 14 days prior to dosing

          -  CrCl < 20ml/min or < 20ml/min/1.73 m2 at Screening
Clinical trial NCT00645229 (phase 3, status: terminated)
Conditions: schizophrenia, schizoaffective disorder
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9, F25.9, F25.0, F25.1, F25.8
Drugs: ziprasidone
SMILES: ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1
Reason stopped: 
    please see detailed description for termination reason.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients not currently being treated with antipsychotic medication and neuroleptic
             naive patients

          -  Diagnosis of schizophrenia or schizoaffective disorder

          -  Antipsychotic treatment prior to screening was to be for a cumulative period of less
             than 5 years

        Exclusion Criteria:

          -  Patients at immediate risk of committing harm to self or others

          -  Treatment with clozapine within 3 months prior to baseline

          -  History of neuroleptic treatment

          -  Current antipsychotic treatment
Clinical trial NCT00301223 (phase 3, status: completed)
Conditions: neuropathic pain
ICD codes: E85.1, E85.0, N31.0, N31.1, N31.2, E10.610, E11.610
Drugs: pregabalin
SMILES: NCC1(CC(O)=O)CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Chinese outpatient of age 18 to 75

          -  At screening and baseline, a score of greater than 40 mm on the visual log scale of
             SF-MPQ

        Exclusion Criteria:

          -  Neurologic disorders unrelated to neuropathic pain, which in the opinion of the
             investigator, might impair the assessment of pain

          -  Serum creatinine clearance greater than 60 ml/min
Clinical trial NCT01687296 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: fluticasone propionate inhalation solution, oral prednisone, placebo inhalation solution, placebo tablet, salbutamol
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC1=CC(O)=CC(C)=C1Cl, CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Chinese male and female pediatric or adolescent subjects aged 4 to 16 years, inclusive

          -  Subjects have an established diagnosis of asthma

          -  The definition of asthma. According to Chinese Guideline for the diagnosis and optimal
             management of asthma in children [Respiratory branch of pediatric society,Chinese
             Medical. Association. 2008, revised version], the subjects can be diagnosed when
             meeting the criteria. The diagnosis criteria is listed in the protocol.

          -  The severity of an acute exacerbation of asthma is defined as PEF of 50% to 75%
             predicted via a peak flow meter, with a clinical scoring index of ≥2. The clinical
             scoring index represents the sum of the score for each of four signs: respiratory rate
             (0=low to 3=high, dependent on age), wheezing (0=none to 3=severe),
             inspiration/expiration ratio (0=2:1 to 3=1:3), and accessory muscle (0=none to
             3=marked use).

          -  Subjects can properly use a mini-wright peak flow meter, nebulizer and MDI
             with/without a spacer, and accurately complete a diary card with parental assistance,
             if required.

          -  Subjects' parents/guardians are willing to give written informed consent.

        Exclusion criteria:

          -  Severe respiratory dysfunction.

          -  History of mechanical ventilation due to respiratory failure.

          -  Admission to hospital due to respiratory disease within the previous 2 weeks,
             including asthmatic exacerbations.

          -  Clinical or lab evidence of a serious, uncontrolled systemic disease or presence of
             any disease likely to interfere with the objectives of this study, such as pulmonary
             cystic fibrosis and bronchopulmonary dysplasia.

          -  Known or suspected hypersensitivity to glucocorticosteroids or β2 agonists.

          -  Clinical visual evidence of oral candidiasis at Visit1.

          -  Use of the medications below in Table 1 according to the following defined time
             intervals prior to presentation. The list is provided in the protocol.